Advertisement
Table 4 Patients characteristics related to morality
| Clinical features | Death group(n = 10) | Survival group | P value |
|---|---|---|---|
| (n = 12) | |||
| Male/Female(n) | 7(70.0%)/3(30.0%) | 8(80.0%)/4(40.0%) | 1.000 |
| Age (years) | 53 ± 12.9(33~70) | 40 ± 14.7(25~70) | 0.050 |
| Duration (weeks) | 19 ± 24.8(10~48) | 34 ± 69.2(0.83~216) | 0.547 |
| Extrapulmonary manifestations (n) | |||
| Fever | 3 (30.0%) | 7 (58.3%) | 0.231 |
| Skin lesions (purpura, gangrene, ulceration) | 3 (30.0%) | 3 (25.0%) | 1.000 |
| Ear (hearing loss, otitis media) | 2 (20.0%) | 4 (33.3%) | 0.646 |
| Nasal and sinus involvement | 5 (50.0%) | 7 (58.3%) | 1.000 |
| Oral ulceration | 4 (40.0%) | 1 (8.3%) | 0.135 |
| glomerulonephritis | 6 (60.0%) | 6 (50.0%) | 0.691 |
| Nervous system (facial paralysis, multiple mononeuropathy, etc.) | 3 (30.0%) | 1 (8.3%) | 0.293 |
| Arthralgia/arthritis | 4 (40.0%) | 4 (33.3%) | 1.000 |
| Parotid swelling and pain | 2 (20.0%) | 0 (0.0%) | 0.195 |
| ESR(mm/h) | 104 ± 26.7 | 82 ± 33.9 | 0.233 |
| Infection(n) | 6 (60.0%) | 3 (25.0%) | 0.192 |
| Corticosteroids and Immunosuppressants (n) | |||
| steroid pulse therapy | 1 (10.0%) | 4 (33.3%) | 0.323 |
| treatment interruption | 2/4(50.0%) | 0/8(0.0%) | 0.091 |
| Non-response to Pleural drainage (n) | 5/5 (100%) | 0/7 (0.0%) | 0.010 |
| Surgery(n) | 2 (20.0%) | 5 (41.7%) | 0.381 |
